Riskpilot← Back to searchSign inGet full accessLab Vision Aktiebolag
ABActiveOrg 5564872884Torsby Sjöväg 4 DWholesale of pharmaceutical and medical goods · NACE 4646Est. 19940 employees
Revenue 2024
SEK 1,7M
-34% vs 2023
EBITDA margin
43.7%
+279% vs 2023
Equity ratio
76.5%
Financial strength
Net profit 2024
SEK 605K
-36% vs 2023
| Revenue | SEK 1,7M | -34% |
| EBITDA | SEK 734K | +279% |
| Net profit | SEK 605K | -36% |
| Total assets | SEK 2,5M | -24% |
| Equity | SEK 1,9M | -26% |
| Employees | 0 | — |
Legal name
Lab Vision Aktiebolag
Org number
5564872884
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4 maj 1994
Share capital
SEK 54 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är försäljning av analysinstrument till laboratorier och processindustri, jämte därmed förenlig verksamhet.
Address
Torsby Sjöväg 4 D
Phone
+46857400990
Email
labvision@labvision.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 964 | 6 257 | 7 664 | 2 544 | 1 680 |
| Staff expenses | — | — | — | −440 | −19 |
| EBITDA | 489 | 1 020 | 1 542 | −411 | 734 |
| Depreciation & amort. | −33 | −24 | −31 | −6 | −6 |
| EBIT | 456 | 996 | 1 511 | −417 | 729 |
| Net financials | −35 | 18 | 52 | 1 604 | 35 |
| Profit before tax | 421 | 1 013 | 1 564 | 1 187 | 764 |
| Tax | −108 | −219 | −330 | −248 | −159 |
| Net profit | 313 | 794 | 1 234 | 940 | 605 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 461 | 2 838 | 4 147 | 3 330 | 2 541 |
| Equity | 1 072 | 1 866 | 2 700 | 2 640 | 1 945 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 1 389 | 972 | 1 447 | 690 | 596 |
| Total debt | 1 389 | 972 | 1 447 | 690 | 596 |
EBITDA margin
43.7%
This company
15.8%
Market median
+177% vs market
20202024
Equity ratio
76.5%
This company
38.2%
Market median
+100% vs market
20202024
Return on equity
31.1%
This company
18.4%
Market median
+69% vs market
20202024
Net profit margin
36.0%
This company
8.1%
Market median
+344% vs market
20202024
Asset turnover
0.66×
This company
1.12×
Market median
-41% vs market
20202024
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
US Audit | Audit | 2022 |
TE Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lab Vision Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Strauss | Audit | 0 companies |
| Tomas Erik Englund | Chief Executive Officer | 0 companies |
| Lena Christina Englund | Deputy Board Member | 0 companies |